<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pulmo</journal-id><journal-title-group><journal-title xml:lang="ru">Пульмонология</journal-title><trans-title-group xml:lang="en"><trans-title>PULMONOLOGIYA</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0869-0189</issn><issn pub-type="epub">2541-9617</issn><publisher><publisher-name>Scientific and Practical Journal “PULMONOLOGIYA” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18093/0869-0189-2022-32-5-705-715</article-id><article-id custom-type="elpub" pub-id-type="custom">pulmo-2726</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Особенности и задачи организации обеспечения больных раком легких в период пандемии COVID-19 в российском регионе</article-title><trans-title-group xml:lang="en"><trans-title>Arrangement and objectives of providing patients with lung cancer with treatment during the COVID-19 pandemic in the Russian region</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1243-743X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Старцев</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Startsev</surname><given-names>V. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Старцев Владимир Юрьевич – доктор медицинских наук, профессор кафедры онкологии, детской онкологии и лучевой терапии Федерального государственного бюджетного образовательного учреждения высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации, заведующий кафедрой урологии Частного образовательного учреждения высшего образования «Санкт-Петербургский медико-социальный институт»</p><p>194100, Санкт-Петербург, ул. Литовская, 2, </p><p>195271, Санкт-Петербург, Кондратьевский пр., 72, лит. «А» </p></bio><bio xml:lang="en"><p>Vladimir Yu. Startsev, Doctor of Medicine, Professor, Department of Oncology, Pediatric Oncology and Radiation Therapy, Federal State budgetary Educational Institution of Higher Education “St. Petersburg State Pediatric Medical University” of the Ministry of Healthcare of the Russian Federation, Head of the Department of Urology, Private University Saint-Petersburg Medico-Social Institute</p><p>ul. Litovskaya 2, Saint-Petersburg, 194100,</p><p>Kondrat’evskiy pr. 72 lit. “A”, Saint-Petersburg, 195271</p></bio><email xlink:type="simple">doc.urolog@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0685-490X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голубев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golubev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голубев Сергей Владимирович – заместитель министра</p><p>685000, Магадан, ул. Пролетарская, 14 </p></bio><bio xml:lang="en"><p>Sergey V. Golubev, Deputy Minister</p><p>ul. Proletarskaya 14, Magadan, 685000</p></bio><email xlink:type="simple">golubevsv@49gov.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава Российской Федерации;&#13;
Частное образовательное учреждение высшего образования «Санкт-Петербургский медико-социальный институт»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation;&#13;
Private University Saint-Petersburg Medico-Social Institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Министерство здравоохранения и демографической политики Магаданской области</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ministry of Health and Demographic Policy of the Magadan Region</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2022</year></pub-date><volume>32</volume><issue>5</issue><fpage>705</fpage><lpage>715</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Старцев В.Ю., Голубев С.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Старцев В.Ю., Голубев С.В.</copyright-holder><copyright-holder xml:lang="en">Startsev V.Y., Golubev S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.pulmonology.ru/pulm/article/view/2726">https://journal.pulmonology.ru/pulm/article/view/2726</self-uri><abstract><p>Деятельность онкологической службы в Российской Федерации осложнилась в связи с развитием новой коронавирусной инфекции, вызванной Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2). Диагностика злокачественных новообразований легких (ЗНОЛ) ухудшилась, поскольку медицинские учреждения были переориентированы на противоэпидемический режим.</p><p>Целью исследования явилась оценка особенностей оказания медицинской помощи при ЗНОЛ жителям Магаданской области (МагО) в период пандемии НКИ.</p><sec><title>Материалы и методы</title><p>Материалы и методы. На основании сведений из форм государственной статистической отчетности № 7 и № 35 проведен анализ данных по пациентам со ЗНОЛ, содержащихся в медицинских информационно-аналитических центрах МагО. Изучены материалы публикаций за 2019–2021 гг., собранные в базах данных Medline, CrossRef, Pubmed и Scopus. Определены общие проблемы онкологической службы МагО, обозначены пути решения.</p></sec><sec><title>Результаты</title><p>Результаты. В структуре заболеваемости ЗНО в 2014–2020 гг. у жителей МагО лидируют опухоли легких. В 2019 г. «грубый» показатель заболеваемости ЗНОЛ (58,8 на 100 тыс. населения; прирост относительно 2009 г. – +20,74 %) и относительная доля опухолей, выявленных в 2020 г. в локализованных стадиях, опережали средние значения по Российской Федерации. В 2018–2021 гг. показатель морфологической верификации ЗНОЛ и удельный вес такой патологии в запущенных стадиях продолжали расти, однако показатель одногодичной летальности ЗНО снизился. В 2021 г. низкодозная компьютерная томография (КТ) органов грудной клетки проведена 10,3 % жителей МагО (выявлено 10 (1,8 %) случаев ЗНОЛ). Локализованные ЗНОЛ определялись в 32,5 % случаев в 2021 г. (24,5 % – в 2020 г., 20,3 % – в 2019 г.). Распространение НКИ затруднило деятельность сотрудников онкослужбы МагО в связи с необходимостью дистанционно консультировать пациентов, проживающих вдали от регионального центра (Магадана). Констатированы недоукомплектованность лечебных учреждений оборудованием для низкодозной КТ, недостатки кадрового состава лечебно-профилактических учреждений, недостаточное использование возможностей химиотерапии в лечении пациентов с ЗНОЛ, а также проблемы паллиативной помощи больным с запущенными стадиями опухоли.</p></sec><sec><title>Заключение</title><p>Заключение. Основными проблемами онкологической службы МагО являются кадровый дефицит, недостаточная укомплектованность оборудованием и отсутствие единого информационного поля в лечебных учреждениях. Указанные проблемы специализированной медицинской помощи пациентам с ЗНОЛ предстоит решать сотрудникам регионального Министерства здравоохранения, научных школ и вузов страны.</p></sec></abstract><trans-abstract xml:lang="en"><p>The operation of the oncological services of the Russian Federation were complicated by the spread of the Severe Acute Respiratory Syndrome CoronaVirus-2, which worsened the diagnosis of lung cancer and led to the reorientation of medical institutions to the anti-epidemic mode.</p><sec><title>The aim</title><p>The aim. To evaluate the features of providing medical care for lung cancer to residents of the Magadan Region during the pandemic of COronaVIrus Disease-19 (COVID-19).</p></sec><sec><title>Methods</title><p>Methods. The analysis of the Magadan Region database on patients with lung cancer was carried out. The databased is filled in with the information from state statistical reporting forms No.7 and No.35. General problems of the Magadan Region healthcare system were identified using materials of publications from the Medline, CrossRef, Pubmed and Scopus databases for 2019 – 2021; the potential solutions were also suggested.</p></sec><sec><title>Results</title><p>Results. The analysis of the incidence of malignant neoplasms in 2014 – 2020 yy. showed that lung tumors are in the lead among Magadan Region residents. The “rough” incidence rate of lung cancer in 2019 (58.8 per 100,000 inhabitants an increase from 2009 +20.74%) and the relative proportion of these tumors detected in 2020 in localized stages are ahead of the average values for the Russian Federation. In 2018 – 2021, the indicator of morphological verification of lung cancer and the proportion of advanced tumors continued to increase, but the one-year mortality rate was decreasing. In 2021, 10.3% of the residents of Magadan Region had low-dose computed tomography (CT) of the chest organs. 10 (1.8%) cases of lung cancer were detected. Localized lung cancer was detected in 32.5% of those cases (2020 – 24.5%, 2019 – 20.3%). The spread of the coronavirus infection has complicated work of the staff of the Magadan Region oncology service: remote medical consultations for patients living far from the regional center (Magadan) are to be developed. Insufficient number of low-dose CT machines in the medical institutions, understaffing in health facilities, insufficient use of chemotherapy in the treatment of patients with lung cancer, as well as problems of palliative care for patients with advanced stages of the tumor were identified.</p></sec><sec><title>Conclusion</title><p>Conclusion. The main problems of the oncological service of the Magadan Region are the shortage of personnel, lack of equipment and the lack of a single information field in the medical institutions. These problems of specialized medical care for patients with lung cancer will have to be solved by the regional Ministry of Health, scientific schools, and universities.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>активная выявляемость</kwd><kwd>злокачественные новообразования</kwd><kwd>Магаданская область</kwd><kwd>рак легких</kwd><kwd>паллиативная помощь</kwd><kwd>организация медицинской помощи</kwd><kwd>пандемия COVD-19</kwd><kwd>одногодичная летальность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>active detection</kwd><kwd>malignant neoplasms</kwd><kwd>Magadan Region</kwd><kwd>lung cancer</kwd><kwd>palliative care</kwd><kwd>organization of medical care</kwd><kwd>COVID-19 pandemic</kwd><kwd>one-year mortality</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.</mixed-citation><mixed-citation xml:lang="en">Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020; 323 (20): 2052–2059. DOI: 10.1001/jama.2020.6775.</mixed-citation><mixed-citation xml:lang="en">Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020; 323 (20): 2052–2059. DOI: 10.1001/jama.2020.6775.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68 (6): 394–424. DOI: 10.3322/caac.21492.</mixed-citation><mixed-citation xml:lang="en">Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68 (6): 394–424. DOI: 10.3322/caac.21492.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Allemani C., Matsuda T., Di Carlo V. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391 (10125): 1023–1075. DOI: 10.1016/S0140-6736(17)33326-3.</mixed-citation><mixed-citation xml:lang="en">Allemani C., Matsuda T., Di Carlo V. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391 (10125): 1023–1075. DOI: 10.1016/S0140-6736(17)33326-3.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Arnold M., Rutherford M. J., Bardot A. et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995– 2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019; 20 (11): 1493–1505. DOI: 10.1016/S1470-2045(19)30456-5.</mixed-citation><mixed-citation xml:lang="en">Arnold M., Rutherford M. J., Bardot A. et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019; 20 (11): 1493–1505. DOI: 10.1016/S1470-2045(19)30456-5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">NHS England. Monthly provider based data and summaries. England; 2020. Available at: https://www.england.nhs.uk/statistics/statisticalwork-areas/cancer-waiting-times/monthly-prov-cwt. [Accessed: August 14, 2021].</mixed-citation><mixed-citation xml:lang="en">NHS England. Monthly provider based data and summaries. England; 2020. Available at: https://www.england.nhs.uk/statistics/statisticalwork-areas/cancer-waiting-times/monthly-prov-cwt. [Accessed: August 14, 2021].</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kuderer N.M., Choueiri T.K., Shah D.P. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395 (10241): 1907–1918. DOI: 10.1016/S0140-6736(20)31187-9.</mixed-citation><mixed-citation xml:lang="en">Kuderer N.M., Choueiri T.K., Shah D.P. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395 (10241): 1907–1918. DOI: 10.1016/S0140-6736(20)31187-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Swann R., McPhail S., Witt J. et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br. J. Gen. Pract. 2018, 68: e63–72. DOI: 10.3399/bjgp17X694169.</mixed-citation><mixed-citation xml:lang="en">Swann R., McPhail S., Witt J. et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br. J. Gen. Pract. 2018, 68: e63–e72. DOI: 10.3399/bjgp17X694169.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Majeed A., Maile E.J., Bindman A.B. The primary care response to COVID-19 in England’s National Health Service. J. R. Soc. Med. 2020, 113 (6): 208–210. DOI: 10.1177/0141076820931452.</mixed-citation><mixed-citation xml:lang="en">Majeed A., Maile E.J., Bindman A.B. The primary care response to COVID-19 in England’s National Health Service. J. R. Soc. Med. 2020, 113 (6): 208–210. DOI: 10.1177/0141076820931452.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C., Wang Y., Li X. et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.</mixed-citation><mixed-citation xml:lang="en">Huang C., Wang Y., Li X. et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Liang W., Guan W., Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21 (3): 335–337. DOI: 10.1016/S1470-2045(20)30096-6.</mixed-citation><mixed-citation xml:lang="en">Liang W., Guan W., Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21 (3): 335–337. DOI: 10.1016/S1470-2045(20)30096-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng Z., Peng F., Xu B. et al. Risk factors of critical &amp; mortal COVID-19 cases: a systematic literature review and meta-analysis. J. Infect. 2020; 81: e16–25. DOI: 10.1016/j.jinf.2020.04.021.</mixed-citation><mixed-citation xml:lang="en">Zheng Z., Peng F., Xu B. et al. Risk factors of critical &amp; mortal COVID-19 cases: a systematic literature review and meta-analysis. J. Infect. 2020; 81: e16–e25. DOI: 10.1016/j.jinf.2020.04.021.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">GOV.UK. Guidance on shielding and protecting people whoare clinically extremely vulnerable from COVID-19. Available at: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 [Accessed: September 11, 2021].</mixed-citation><mixed-citation xml:lang="en">GOV.UK. Guidance on shielding and protecting people whoare clinically extremely vulnerable from COVID-19. Available at: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 [Accessed: September 11, 2021].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Состояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. Доступно на: https://oncology-association.ru/wp-content/uploads/2021/10/pomoshh-2020-el.-versiya.pdf</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinskiy V.V., Shakhzadova A.O., eds. [Situation with oncological care in the Russian Federation in 2019]. Moscow: National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2020. Available at: https://oncology-association.ru/wp-content/uploads/2021/10/pomoshh-2020-el.-versiya.pdf (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ali N., Lifford K. J., Carter B. et al. Barriers to uptake among high-risk individuals declining participation in lungcancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open. 2015; 5 (7): e008254. DOI: 10.1136/bmjopen-2015-008254.</mixed-citation><mixed-citation xml:lang="en">Ali N., Lifford K. J., Carter B. et al. Barriers to uptake among high-risk individuals declining participation in lungcancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open. 2015; 5 (7): e008254. DOI: 10.1136/bmjopen-2015-008254.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Crosbie P.A., Balata H., Evison M. et al. Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester. Thorax. 2019; 74 (4): 405–409. DOI: 10.1136/thoraxjnl-2017-211377.</mixed-citation><mixed-citation xml:lang="en">Crosbie P.A., Balata H., Evison M. et al. Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester. Thorax. 2019; 74 (4): 405–409. DOI: 10.1136/thoraxjnl-2017-211377.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzone P.J., Gould M.K., Arenberg D.A. et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020; 158 (1): 406–415. DOI: 10.1016/j.chest.2020.04.020.</mixed-citation><mixed-citation xml:lang="en">Mazzone P.J., Gould M.K., Arenberg D.A. et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020; 158 (1): 406–415. DOI: 10.1016/j.chest.2020.04.020.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chung R.Y., Dong D., Li M.M. Socioeconomic gradient in health and the COVID-19 outbreak. BMJ. 2020; 369: m1329. DOI: 10.1136/bmj.m1329.</mixed-citation><mixed-citation xml:lang="en">Chung R.Y., Dong D., Li M.M. Socioeconomic gradient in health and the covid-19 outbreak. BMJ. 2020; 369: m1329. DOI: 10.1136/bmj.m1329.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">British Thoracic Society. COVID-19: information for the respiratory community. Available at: https://www.brit-thoracic.org.uk/about-us/covid-19-information-for-the-respiratory-community [Accessed: September 09, 2021].</mixed-citation><mixed-citation xml:lang="en">British Thoracic Society. COVID-19: information for the respiratory community. Available at: https://www.brit-thoracic.org.uk/about-us/covid-19-information-for-the-respiratory-community [Accessed: September 09, 2021].</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jones D., Neal R. D., Duffy S.R. et al. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020; 21 (6): 748. DOI: 10.1016/S1470-2045(20)30242-4.</mixed-citation><mixed-citation xml:lang="en">Jones D., Neal R. D., Duffy S.R. et al. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020; 21 (6): 748. DOI: 10.1016/S1470-2045(20)30242-4.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sud A., Torr B., Jones M.E. et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020; 21 (8): 1034–1044. DOI: 10.1016/S1470-2045(20)30392-2.</mixed-citation><mixed-citation xml:lang="en">Sud A., Torr B., Jones M.E. et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020; 21 (8): 1034–1044. DOI: 10.1016/S1470-2045(20)30392-2.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Maconachie R., Mercer T., Navani N. et al. Lung cancer: diagnosis and management: summary of updated NICE guidance. BMJ. 2019; 364: 11049. DOI: 10.1136/bmj.l1049.</mixed-citation><mixed-citation xml:lang="en">Maconachie R., Mercer T., Navani N. et al. Lung cancer: diagnosis and management: summary of updated NICE guidance. BMJ. 2019; 364: 11049. DOI: 10.1136/bmj.l1049.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lei S., Jiang F., Su W. et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020; 21: 100331. DOI: 10.1016/j.eclinm.2020.100331.</mixed-citation><mixed-citation xml:lang="en">Lei S., Jiang F., Su W. et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020; 21: 100331. DOI: 10.1016/j.eclinm.2020.100331.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">NIHR Global Health Research Unit on Global Surgery. About COVIDSurg. Available at: https://globalsurg.org/covidsurg [Accessed: September 09, 2021].</mixed-citation><mixed-citation xml:lang="en">NIHR Global Health Research Unit on Global Surgery. About CovidSurg. Available at: https://globalsurg.org/covidsurg [Accessed: September 09, 2021].</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Albiges L., Foulon S., Bayle A. et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nat. Cancer. 2020; 1 (10): 965–975. DOI: 10.1038/s43018-020-00120-5.</mixed-citation><mixed-citation xml:lang="en">Albiges L., Foulon S., Bayle A. et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nat. Cancer. 2020; 1 (10): 965–975. DOI: 10.1038/s43018-020-00120-5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Horn L., Whisenant J.G., Torri V. et al. Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy on survival. Am. Soc. Clin. Oncol. 2020; 38 (18, Suppl.): LBA111. DOI: 10.1200/JCO.2020.38.18_suppl.LBA111.</mixed-citation><mixed-citation xml:lang="en">Horn L., Whisenant J.G., Torri V. et al. Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy on survival. Am. Soc. Clin. Oncol. 2020; 38 (18, Suppl.): LBA111. DOI: 10.1200/JCO.2020.38.18_suppl.LBA111.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">NHS England Interim treatment change options during the COVID-19 pandemic, endorsed by NHS EnglandInterim treatment change options during the COVID-19 pandemic, endorsed by NHS England. Available at: https://www.genesiscare.com/content/dam/pdfs/uk/UK_interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381.pdf [Accessed: September 09, 2021].</mixed-citation><mixed-citation xml:lang="en">NHS England Interim treatment change options during the COVID-19 pandemic, endorsed by NHS EnglandInterim treatment change options during the COVID-19 pandemic, endorsed by NHS England. Available at: https://www.genesiscare.com/content/dam/pdfs/uk/UK_interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381.pdf [Accessed: September 09, 2021].</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Faivre-Finn C., Fenwick J.D., Franks K.N. et al. Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic. Clin. Oncol. (R. Coll. Radiol.) 2020; 32 (8): 481–489. DOI: 10.1016/j.clon.2020.05.001.</mixed-citation><mixed-citation xml:lang="en">Faivre-Finn C., Fenwick J.D., Franks K.N. et al. Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic. Clin. Oncol. (R. Coll. Radiol.) 2020; 32 (8): 481–489. DOI: 10.1016/j.clon.2020.05.001.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kasivisvanathan V., Lindsay J., Rakshani-Moghadam S. et al. A cohort study of 30 day mortality after non-emergency surgery in a COVID-19 cold site. Int. J. Surg. 2020; 84: 57–65. DOI: 10.1016/j.ijsu.2020.10.019.</mixed-citation><mixed-citation xml:lang="en">Kasivisvanathan V., Lindsay J., Rakshani-Moghadam S. et al. A cohort study of 30 day mortality after non-emergency surgery in a COVID-19 cold site. Int. J. Surg. 2020; 84: 57–65. DOI: 10.1016/j.ijsu.2020.10.019.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ironmonger L., Ohuma E., Ormiston-Smith N. et al. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br. J. Cancer. 2015; 112 (1): 207–216. DOI: 10.1038/bjc.2014.596.</mixed-citation><mixed-citation xml:lang="en">Ironmonger L., Ohuma E., Ormiston-Smith N. et al. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br. J. Cancer. 2015; 112 (1): 207–216. DOI: 10.1038/bjc.2014.596.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Chou Y.C., Yen Y.F., Feng R.C. et al. Impact of the COVID-19 pandemic on the utilization of hospice care services: a cohort study in Taiwan. J. Pain Symptom Manage. 2020; 60 (3): e1–6. DOI: 10.1016/j.jpainsymman.2020.07.005.</mixed-citation><mixed-citation xml:lang="en">Chou Y.C., Yen Y.F., Feng R.C. et al. Impact of the COVID-19 pandemic on the utilization of hospice care services: a cohort study in Taiwan. J. Pain Symptom Manage. 2020; 60 (3): e1–6. DOI: 10.1016/j.jpainsymman.2020.07.005.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Brighton L.J., Miller S., Farquhar M. et al. Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis. Thorax. 2019; 74 (3): 270–281. DOI: 10.1136/thoraxjnl-2018-211589.</mixed-citation><mixed-citation xml:lang="en">Brighton L.J., Miller S., Farquhar M. et al. Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis. Thorax. 2019; 74 (3): 270–281. DOI: 10.1136/thoraxjnl-2018-211589.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson H., Brighton L., Clark J. et al. Experiences, concerns and priorities for palliative care research during the COVID-19 pandemic: a rapid virtual stakeholder consultation with people affected by serious Illness in England. London: King’s College London; 2020. DOI: 10.18742/pub01-034.</mixed-citation><mixed-citation xml:lang="en">Johnson H., Brighton L., Clark J. et al. Experiences, concerns and priorities for palliative care research during the COVID-19 pandemic: a rapid virtual stakeholder consultation with people affected by serious Illness in England. London: King’s College London; 2020. DOI: 10.18742/pub01-034.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Miaskowski C., Paul S. M., Snowberg K. et al. Stress and symptom burden in oncology patients during the COVID-19 pandemic. J. Pain Symptom Manage. 2020; 60 (5): e25–34. DOI: 10.1016/j.jpainsymman.2020.08.037.</mixed-citation><mixed-citation xml:lang="en">Miaskowski C., Paul S. M., Snowberg K. et al. Stress and symptom burden in oncology patients during the COVID-19 pandemic. J. Pain Symptom Manage. 2020; 60 (5): e25–34. DOI: 10.1016/j.jpainsymman.2020.08.037.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Marron J.M., Joffe S., Jagsi R. et al. Ethics and resources carcity: ASCO recommendations for the oncology community during the COVID-19 pandemic. J. Clin. Oncol. 2020, 38 (19): 2201–2205. DOI: 10.1200/JCO.20.00960.</mixed-citation><mixed-citation xml:lang="en">Marron J.M., Joffe S., Jagsi R. et al. Ethics and resources carcity: ASCO recommendations for the oncology community during the COVID-19 pandemic. J. Clin. Oncol. 2020, 38 (19): 2201–2205. DOI: 10.1200/JCO.20.00960.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Higginson I., Murtagh F., Preston N. et al. Improving palliative care for people affected by the COVID-19 pandemic by sharing learning the National and International response. Available at: https://www.kcl.ac.uk/cicelysaunders/research/evaluating/covpall-study/covpall-rehab [Accessed: September 10, 2021].</mixed-citation><mixed-citation xml:lang="en">Higginson I., Murtagh F., Preston N. et al. Improving palliative care for people affected by the COVID-19 pandemic by sharing learning the National and International response. Available at: https://www.kcl.ac.uk/cicelysaunders/research/evaluating/covpall-study/covpall-rehab [Accessed: September 10, 2021].</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Birt L., Hall N., Emery J. et al. Responding to symptoms suggestive of lung cancer: a qualitative interview study. BMJ Open Respir. Res. 2014; 1 (1): e000067. DOI: 10.1136/bmjresp-2014-000067.</mixed-citation><mixed-citation xml:lang="en">Birt L., Hall N., Emery J. et al. Responding to symptoms suggestive of lung cancer: a qualitative interview study. BMJ Open Respir. Res. 2014; 1 (1): e000067. DOI: 10.1136/bmjresp-2014-000067.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Hannaford P.C., Thornton A.J., Murchie P. et al. Patterns of symptoms possibly indicative of cancer and associated help-seeking behaviour in a large sample of United Kingdom residents – The USEFUL study. PLoS ONE. 2020; 15 (1): e0228033. DOI: 10.1371/journal.pone.0228033.</mixed-citation><mixed-citation xml:lang="en">Hannaford P.C., Thornton A.J., Murchie P. et al. Patterns of symptoms possibly indicative of cancer and associated help-seeking behaviour in a large sample of United Kingdom residents – The USEFUL study. PLoS ONE. 2020; 15 (1): e0228033. DOI: 10.1371/journal.pone.0228033.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Сunningham Y., Wyke S., Blyth K. G. et al. Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: a qualitative interview study. Psychooncology. 2019; 28 (4): 718–725. DOI: 10.1002/pon.5005.</mixed-citation><mixed-citation xml:lang="en">Сunningham Y., Wyke S., Blyth K. G. et al. Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: a qualitative interview study. Psychooncology. 2019; 28 (4): 718–725. DOI: 10.1002/pon.5005.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Quaife S.L., Marlow L.A.V., Mc Ewen A. et al. Attitudes towardslung cancer screening in socioeconomically deprived and heavy smoking com-munities: informing screening communication. Health Expect. 2017; 20 (4): 563–573. DOI: 10.1111/hex.12481.</mixed-citation><mixed-citation xml:lang="en">Quaife S.L., Marlow L.A.V., Mc Ewen A. et al. Attitudes towardslung cancer screening in socioeconomically deprived and heavy smoking com-munities: informing screening communication. Health Expect. 2017; 20 (4): 563–573. DOI: 10.1111/hex.12481.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">McCutchan G., Smits S., Ironmonger L. et al. Evaluation of a national lung cancer symptom awareness campaign in Wales. Br. J. Cancer. 2020; 122 (4): 491–497. DOI: 10.1038/s41416-019-0676-2.</mixed-citation><mixed-citation xml:lang="en">McCutchan G., Smits S., Ironmonger L. et al. Evaluation of a national lung cancer symptom awareness campaign in Wales. Br. J. Cancer. 2020; 122 (4): 491–497. DOI: 10.1038/s41416-019-0676-2.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Lai A. G., Pasea L., Banerjee A. et al. Estimated impact of theCOVID-19 pandemic on cancer services and excess 1-year mortality in peoplewith cancer and multimorbidity: near real-time data on cancer care, cancerdeaths and a population-based cohort study. BMJ Open. 2020; 10 (11): e043828. DOI: 10.1136/bmjopen-2020-043828.</mixed-citation><mixed-citation xml:lang="en">Lai A. G., Pasea L., Banerjee A. et al. Estimated impact of theCOVID-19 pandemic on cancer services and excess 1-year mortality in peoplewith cancer and multimorbidity: near real-time data on cancer care, cancerdeaths and a population-based cohort study. BMJ Open. 2020; 10 (11): e043828. DOI: 10.1136/bmjopen-2020-043828.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Round Th., L’Esperance V., Bayly J. et al. COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary. Br. J. Cancer. 2021; 125 (5): 629–640. DOI: 10.1038/s41416-021-01361-6.</mixed-citation><mixed-citation xml:lang="en">Round Th., L’Esperance V., Bayly J. et al. COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary. Br. J. Cancer. 2021; 125 (5): 629–640. DOI: 10.1038/s41416-021-01361-6.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
